Details of the Drug

General Information of Drug (ID: DM873BS)

Drug Name

Pervanadate

Synonyms

pervanadate; POV; DTXSID2041092; NOCAS_41092; trisodium trioxido(oxo)vanadium - hydrogen peroxide (1:3)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
1

Molecular Weight

285.95

Logarithm of the Partition Coefficient

Not Available

Rotatable Bond Count

0

Hydrogen Bond Donor Count

6

Hydrogen Bond Acceptor Count

10

Chemical Identifiers

Formula: H6Na3O10V
IUPAC Name: trisodium;hydrogen peroxide;trioxido(oxo)vanadium
Canonical SMILES: OO.OO.OO.[O-][V](=O)([O-])[O-].[Na+].[Na+].[Na+]
InChI: InChI=1S/3Na.3H2O2.4O.V/c;;;3*1-2;;;;;/h;;;3*1-2H;;;;;/q3*+1;;;;;3*-1;
InChIKey: PZYFJWVGRGEWGO-UHFFFAOYSA-N

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein tyrosine phosphatase (PTP)	TTWC6MY	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Amphiregulin (AREG)	OTJFOR67	AREG_HUMAN	Protein Interaction/Cellular Processes	[2]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Post-Translational Modifications	[3]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Post-Translational Modifications	[4]
Receptor tyrosine-protein kinase erbB-4 (ERBB4)	OT9L6C41	ERBB4_HUMAN	Protein Interaction/Cellular Processes	[2]
Tyrosine-protein phosphatase non-receptor type 11 (PTPN11)	OTFH9M73	PTN11_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997 Sep;27(9):2172-9.
2	Tyrosine phosphorylation and proteolysis. Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin. J Biol Chem. 1998 Aug 7;273(32):20589-95. doi: 10.1074/jbc.273.32.20589.
3	Epidermal growth factor receptor activation by diesel particles is mediated by tyrosine phosphatase inhibition. Toxicol Appl Pharmacol. 2008 Dec 15;233(3):382-8. doi: 10.1016/j.taap.2008.09.013. Epub 2008 Sep 26.
4	Double-edged sword effect of biochanin to inhibit nuclear factor kappaB: suppression of serine/threonine and tyrosine kinases. Biochem Pharmacol. 2012 May 15;83(10):1383-92. doi: 10.1016/j.bcp.2012.02.011. Epub 2012 Feb 22.
5	Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A. J Adv Res. 2021 Jun 11;34:79-91. doi: 10.1016/j.jare.2021.06.004. eCollection 2021 Dec.